| 摘要 |
The present invention relates to a new pharmaceutical formulation comprising a lipid aggregate of a negatively charged lipid or lipid mixture and at least one antigenic, native or recombinant polypeptide which constitute a Helicobacter pylori antigen, and optionally a pharmaceutically acceptable carrier. More specifically the invention relates to a lipid aggregate comprising a surface-exposed antigen with an approximate molecular weight of 29 kDa. Furthermore the invention provides a formulation of a nucleic acid molecule coding for the said polypeptide. The new formulations, which are useful as vaccine formulations, elicit a protective immune response against H. pylori infections, and said vaccine formulations are suitable for both therapeutic and prophylatic use. |
